Efficacy, safety and immunogenicity of a recombinant human papillomavirus bivalent (types 16, 18) vaccine in healthy 18-30-year-old Chinese women: a phase III, double-blind, randomized, controlled trial
InfectologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- BMC infectious diseases
- Publicado em
- 18 dez 2025
- Citações
- 1
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Efficacy, safety and immunogenicity of a recombinant human papillomavirus bivalent (types 16, 18) vaccine in healthy 18-30-year-old Chinese women: a phase III, double-blind, randomized, controlled trial
Liwei Shi, Xuefen Gao, Lili Huang, Zhao Gao, Juan Li, Bangwei Yu, Huilan Fan, Guohua Li, Yanxia Wang, Qi Li et al.
Descritores MeSH
- Human papillomavirus 18
- Human papillomavirus 16
- Papillomavirus Vaccines
- Papillomavirus Infections
- Immunogenicity, Vaccine
- Adult
- Antibodies, Viral
- Uterine Cervical Dysplasia
- Uterine Cervical Neoplasms
- China
Veja também
Estudos relacionados
- Head-to-head immunogenicity comparison of one-dose Cecolin and Gardasil in Chinese girls aged 9-14 years: A randomized and open-label clinical trial
- Safety and immunogenicity of a bivalent HPV16/18 vaccine in Chinese females
- Maximizing impact: the power of early HPV vaccination for long-term protection-lessons from a systematic review and meta-regression analysis
- Effects of different-valent vaccines against human papillomavirus (HPV) to prevent persistent HPV16/18 infections and CIN2+ in women: a systematic review and network meta-analysis